<DOC>
	<DOCNO>NCT00859053</DOCNO>
	<brief_summary>The purpose study assess effect hepatic impairment single dose pharmacokinetics BMS-790052 .</brief_summary>
	<brief_title>Single-Dose Pharmacokinetics BMS-790052 Participants With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Key Male female subject age 18 70 year , hepatic impairment conform ChildPugh class A , B C Healthy subject extent possible match first four hepatically impaired subject ChildPugh class regard age ( approximately ± 10 year ) , body weight ( approximately ± 20 % ) gender Key History esophageal gastric variceal bleeding within past 6 month Primarily cholestatic liver disease Active alcoholic hepatitis Stable encephalopathy &gt; = Stage 2 Presence severe ascites edema Presence hepatopulmonary hepatorenal syndrome Positive HCV , unless HCV RNA undetectable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>